Laryngotracheal stenosis repair using cartilage-derived morphogenic proteins: A pilot study.
OBJECTIVE
This pilot study evaluated the role of cartilage-derived morphogenic proteins (CDMPs) as promoters of cartilage growth and differentiation and as a possible alternative to autologous cartilage grafts in laryngotracheal reconstruction.


METHODS
In phase 1, 6 New Zealand rabbits underwent subperichondrial injection of CDMP-1, CDMP-2, or CDMP-3 in the right thyroid ala and normal saline solution in the left thyroid ala as controls. In phase 2, 14 rabbits underwent anterior cricoid split and interposition of a fibrillar collagen sponge saturated with normal saline solution, CDMP-2, or CDMP-3.


RESULTS
In both phases, saline solution failed to induce new cartilage or bone growth. Small foci of cartilage and/or bone formation were observed within the thyroid subperichondria of those rabbits injected with CDMP-2 or CDMP-3. In phase 2, a few small foci of new cartilage and/or bone formation were observed at the edges of the cricoid split with CDMP-2 and CDMP-3.


CONCLUSIONS
A different carrier of CDMP, a change in dosage, or a combination of CDMPs might yield more significant neochondrification. The role of CDMPs as promoters of cartilage and differentiation could not be disqualified in this study and should be further investigated.
Tran
LenhAnh P
LP
Department of Pediatric Otolaryngology, Children's National Medical Center, Washington, DC, USA.
Zalzal
George H
GH
D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005500:Follow-Up Studies; D055428:Growth Differentiation Factor 5; D007267:Injections; D007817:Laryngeal Cartilages; D007829:Laryngostenosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D010865:Pilot Projects; D011817:Rabbits; D014135:Tracheal Stenosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D019485:Bone Morphogenetic Proteins; D055428:Growth Differentiation Factor 5; D016212:Transforming Growth Factor beta; C493866:cartilage-derived morphogenetic protein-3 protein, mouse; C090394:cartilage-derived-morphogenetic protein-2